— Know what they know.
Not Investment Advice

BCAX NASDAQ

Bicara Therapeutics Inc. Common Stock
1W: +0.9% 1M: -11.8% 3M: +34.6% YTD: +27.2% 1Y: +38.6%
$21.68
+0.84 (+4.03%)
 
Weekly Expected Move ±5.8%
$18 $19 $20 $21 $23
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 37 · $1.2B mcap · 35M float · 1.64% daily turnover · Short 60% of daily vol

Cash Flow Trends

Operating Cash Flow
-$107M -42.9% ▼
Capital Expenditures
$280K -294.4% ▼
3Y CAGR: +13.4%
Free Cash Flow
-$107M -43.2% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$393M -251.6% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$38M-$52M-$68M-$138M
Depreciation & Amort.$10K$19K$56K$406K
Stock-Based Comp.$810K$2M$7M$15M
Change in Working Capital$5M-$10M-$14M$0
Other Non-Cash Items$0$14M-$77K$16M
Operating Cash Flow-$32M-$46M-$75M-$107M
— Investing Activities —
Capital Expenditures-$192K-$586K-$71K-$280K
Acquisitions (Net)$0$0$0$0
Investment Purchases$0$0$0-$318M
Investment Sales$0$0$0$0
Other Investing$0$0$62K$0
Investing Cash Flow-$192K-$586K-$9K-$318M
— Financing Activities —
Net Debt Issuance$0$0$0$0
Stock Repurchased$0$0$0$0
Dividends Paid$0$0$0$0
Other Financing$160K$149K$2M$32M
Financing Cash Flow$32M$272M$334M$32M
Net Change in Cash-$573K$226M$259M-$393M
Cash End of Period$4M$230M$490M$97M
Free Cash Flow-$32M-$46M-$75M-$107M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms